JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Janux Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.74+0.23 (+1.39%)
Close on Oct 19, 2026
- Market cap
- $1.05B
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Janux Therapeutics has not reported a dividend
No dividend per share appears in Janux Therapeutics's annual filings since fiscal 2019.